The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 23, 2025

Filed:

Jan. 30, 2023
Applicant:

Cmg Pharmaceutical Co., Ltd., Seongnam, KR;

Inventors:

Jin Sung Kim, Seoul, KR;

Young Sang Kim, Goyang, KR;

Sungmoo Kim, Seongnam, KR;

Ju Hui Jeong, Seongnam, KR;

Hyun Sook An, Seongnam, KR;

Soojeong Kim, Yongin, KR;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); A61K 31/513 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61P 11/06 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/513 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61P 11/06 (2018.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01);
Abstract

Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: in which R, R, R, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.


Find Patent Forward Citations

Loading…